Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

WASHINGTON, Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Evolent has also granted the initial purchasers in the offering a 30-day option to purchase up to an additional $21.75 million aggregate principal amount of notes. Evolent has increased the size of the offering from $140.0 million to $145.0 million (or $166.75 million if the initial purchasers' option to purchase additional notes is exercised in full).

Read more at prnewswire.com